Biotech RadarJobs updated

COMPANY

ashibio

ashibio.com ↗

Clinical Phase 3

Profile checked Oct 10, 2026

Keywords: Fibrodysplasia Ossificans Progressiva Heterotopic Ossification Andecaliximab

2Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. source ↗
  2. Trial start Phase 2/Phase 3: A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06508021A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Phase 2/Phase 3Active, not recruitingOct 25, 2024Feb 4, 2029 (estimated)
NCT07024407A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.Phase 1/Phase 2RecruitingMay 14, 20252025-12 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback